Trulieve Cannabis Corp. — Drug Manufacturers - Specialty & Generic. Scored on the same transparent 7-signal model behind the daily rankings.
★
TRLV
Trulieve Cannabis Corp. · Drug Manufacturers - Specialty & Generic
FCF$129mC
Rev-1.4%D+
D/E0.55B
P/S1.4xA-
PEG——
53.4Score
$8.63$1.7B
1Y Target$19.45Analyst consensus · 5 analysts
5Y Target$34.02Compound horizon
10Y Target$86.27Long-dated conviction
FCF$129mTTMC
FCF $129m — modest; watch for margin expansion
Rev-1.4%TTM YoYD+
Revenue -1.4% — shrinking; needs a catalyst to reverse
D/E0.55B
D/E 0.55 — near the Healthcare debt median (≈60th pctile)
P/S1.4xA-
P/S 1.4x — cheaper than most Healthcare peers (≈25th pctile)
PEG——
PEG not meaningful — earnings growth negative or data unavailable
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 53.4
Quality0.42
Growth0.40
Value0.91
Entry · Margin of safety
52-week rangeMid-range
35% off the 12-month high
vs DCF fair value14% belowest. fair value ~$10
What the price assumes: free cash flow compounding at ~11% a year for the next decade — vs the ~24% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability25% · Bgross profit ÷ total assets (Novy-Marx)
ROIC8.6% · Breturn on invested capital — not score-weighted
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 35% from 52-week high of $13.28 — deep drawdown territory. 5 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $19.45 (implying +125% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -7.4%) — path to GAAP profitability is the core thesis risk. Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.66 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon
1-3 yr $19.45 (5-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $34.02 — requires the platform / technology to reach commercial scale. 10 yr $86.27 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · TRLV
Trend
+1.2 over 20 daily scores
From 52.2 (Jun 22) → 53.4 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · TRLV
$
%
%
Shares to buy
231
Position size
$1,994
4.0% of portfolio
Stop price
$6.47
25% below $8.63
$ at risk if stopped
$498.38
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Trulieve Cannabis Corp. (TRLV) is a Drug Manufacturers - Specialty & Generic company that scores 53.4 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/S (A-), while Rev (D+) rate weaker. On valuation, TRLV sits about 14% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 11% annual free-cash-flow growth over the next decade.
Is TRLV a good stock to buy?
Bull Rankings scores TRLV 53.4 out of 100 on its quality-growth model, which is a middling reading. That is driven by P/S (A-). A score is a quantitative screen of Trulieve Cannabis Corp.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does TRLV score 53.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). TRLV earns its highest marks on P/S (A-), and is held back by Rev (D+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is TRLV overvalued or undervalued?
Based on $8.63, TRLV sits about 14% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 11% annual free-cash-flow growth over the next decade. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in TRLV?
Currently unprofitable (margin -7.4%) — path to GAAP profitability is the core thesis risk. Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.66 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.